Bicycle Therapeutics plc announced on April 16, 2024, Veronica Jordan, Ph.D. notified the Board of Directors of the Company (the Board") of her decision to resign as a Class I director of the Company and as the Chair of the Compensation Committee of the Board and as a member of the Audit Committee of the Board, effective as of the close of business on April 17, 2024, New York City time. Dr. Jordan's decision to resign from the Board was not the result of any disagreement between Dr. Jordan and the Company, its management, the Board or any committees thereof on any matter relating to the Company's operations, policies or practices. Dr. Jordan will continue to serve the Company as a consultant pursuant to a consulting agreement.

On April 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Company (the NCGC"), appointed Felix J. Baker, Ph.D. to the Board, effective as of April 18, 2024, New York City time. Dr. Baker, whose appointment fills the vacancy created by the resignation of Dr. Jordan, will serve as a Class I director until the Company's 2026 annual general meeting of shareholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. The Board has determined that Dr. Baker is independent" pursuant to the rules of the Nasdaq Stock Market LLC and other governing laws and applicable regulations.

Dr. Baker will be a member of the NCGC and of the Scientific Committee of the Board. Concurrently with the resignation of Dr. Jordan and appointment of Dr. Baker, and effective as of April 18, 2024, New York City time, the Board's standing committees are as follows: Audit Committee: Richard Kender (Chair), Stephen Sands and Janice Bourque. Compensation Committee: Janice Bourque (Chair), Richard Kender and Jose-Carlos Gutierrez-Ramos.

Nominating and Corporate Governance Committee: Jose-Carlos Gutierrez-Ramos (Chair), Janice Bourque and Felix J. Baker.